FGF23 as a novel therapeutic target

Advances in Experimental Medicine and Biology

Volumn 728, Issue , 2012, Pages 158-170

  Shimada, Takashi ^a   Fukumoto, Seiji ^b  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR ANTIBODY; FIBROBLAST GROWTH FACTOR RECEPTOR; NEUTRALIZING ANTIBODY; RECOMBINANT FIBROBLAST GROWTH FACTOR 23; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; FIBROBLAST GROWTH FACTOR;

ARTICLE; CANCER SURGERY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; HORMONE SUBSTITUTION; HYPOPHOSPHATEMIA; HYPOPHOSPHATEMIC RICKETS; NONHUMAN; ONCOGENIC OSTEOMALACIA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; TUMOR CALCINOSIS; X LINKED HYPOPHOSPHATEMIC RICKETS; ANIMAL; BLOOD; DRUG ANTAGONISM; HUMAN; IMMUNOLOGY; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; REVIEW;

ANIMALS; ANTIBODIES, NEUTRALIZING; FIBROBLAST GROWTH FACTORS; HORMONE REPLACEMENT THERAPY; HUMANS; MOLECULAR TARGETED THERAPY; RECOMBINANT PROTEINS;

EID: 84859540790     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-0887-1_10     Document Type: Article

References (84)

1. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the'ventrolateral thalamic nucleus ofthe brain. BiochemBiophys Res Commun2000; 277:494-498
2. The ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000; 26:345-348
3. White KE, Jonsson KB, Carn G et al. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 2001; 86:497-500
4. Shimada T, Mizutani S, Muto T et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001; 98:6500-6505
5. Shimada T, Muto T, Urakawa I et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 2002; 143:3179-3182
6. Bai XY, Miao D, Goltzman D et al. The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 2003; 278:9843-9849
7. Bai X, Miao D, Li J et al. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 2004; 145:5269-5279
8. Larsson T, Marsell R, Schipani E et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the alphal(I) collagen promoter exhibit growth retardation, osteomalacia and disturbed phosphate homeostasis. Endocrinology 2004; 145:3087-3094
9. Shimada T, Urakawa I, Yamazaki Y et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 2004; 314:409-414
10. Yamamoto T, Imanishi Y, Kinoshita E et al. The role of fibroblast growth factor 23 for hypophosphatemia and abnormal regulation of vitamin D metabolism in patients with McCune-Albright syndrome. J Bone Miner Metab 2005; 23:231-237
11. Weber TJ, Liu S, Indridason OS et al. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 2003; 18:1227-1234
12. Riminucci M, Collins MT, Fedarko NS et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003; 112:683-692
13. Jonsson KB, Zahradnik R, Larsson T et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003; 348:1656-1663
14. Yamazaki Y, Okazaki R, ShibataM et al. Increased circulatory level ofbiologically active full-length FGF-23 inpatients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002; 87:4957-4960
15. Endo I, Fukumoto S, Ozono K et al. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone 2008; 42:1235-1239
16. Burnett SM, Gunawardene SC, Bringhurst FR et al. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006; 21:1187-1196
17. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005; 90:1519-1524
18. Shimada T, Kakitani M, Yamazaki Y etal. Targeted ablation ofFgf23 demonstrates an essential physiological role ofFGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004; 113:561-568
19. Sitara D, Razzaque MS, Hesse M et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 2004; 23:421-432
20. Lyles KW, Burkes EJ, Ellis GJ et al. Genetic transmission of tumoral calcinosis: autosomal dominant with variable clinical expressivity. J Clin Endocrinol Metab 1985; 60:1093-1096
21. Slavin RE, Wen J, Kumar D et al. Familial tumoral calcinosis. A clinical, histopathologic and ultrastructural study with an analysis of its calcifying process and pathogenesis. Am J Surg Pathol 1993; 17:788-802
22. Topaz O, Shuman DL, Bergman R et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 2004; 36:579-581
23. Araya K, Fukumoto S, Backenroth R et al. A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab 2005;90:5523-5527
24. Benet-Pages A, Orlik P, Strom TM et al. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 2005; 14:385-390
25. ChefetzI, Heller R, Galli-TsinopoulouAetal. A novel homozygous missense mutationinFGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcification. Hum Genet 2005; 118:261-266
26. Larsson T, Davis SI, Garringer HJ et al. Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed. Endocrinology 2005; 146:3883-3891
27. Larsson T, Yu X, Davis SI et al. A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol Metab 2005; 90:2424-2427
28. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117:4003-4008
29. Krajisnik T, Bjorklund P, Marsell R et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007; 195:125-131
30. Saito H, Kusano K, Kinosaki M et al. Humanfibroblast growth factor-23 mutants suppressNa+-dependent phosphate cotransport activity and 1alpha, 25-dihydroxyvitamin D3 production. J Biol Chem 2003; 278:2206-2211
31. Shimada T, Hasegawa H, Yamazaki Y et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19:429-435
32. Bikle D, Adams J, Christakos S. Vitamin D: Production, metabolism, mechanism of action and clinical requirements. In: Seeman E, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7th ed. Washington D.C.: The American Society for Bone and Research, 2008; 141-149
33. Favus M, Bushinsky DA, Lemann J. Regulation of calcium, magnesium and phosphate metabolism. In: Christakos S, HolickMF, eds. Primer on the Metabolic Bone Diseases and Disorders ofMineral Metabolism, sixth ed. Washington, D.C.: the American Society for Bone and Mineral Research, 2006; 76-83
34. Miyamoto K, Ito M, Tatsumi S et al. New aspect of renal phosphate reabsorption: the type IIc sodium-dependent phosphate transporter. Am J Nephrol 2007; 27:503-515
35. Tenenhouse HS. Phosphate transport: molecular basis, regulation and pathophysiology. J Steroid Biochem Mol Biol 2007; 103:572-577
36. Beck L, Karaplis AC, AmizukaN et al. Targeted inactivation ofNpt2 in mice leads to severe renal phosphate wasting, hypercalciuria and skeletal abnormalities. Proc Natl Acad Sci USA 1998; 95:5372-5377
37. Segawa H, Onitsuka A, Furutani J et al. Npt2a and Npt2c in mice play distinct and synergistic roles in inorganic phosphate metabolism and skeletal development. Am J Physiol Renal Physiol2009;297:F671-678
38. Bergwitz C, Roslin NM, Tieder M et al. SLC34A3 mutations in patients with hereditary hypophosphatemic ricketswithhypercalciuriapredictakeyroleforthe sodium-phosphatecotransporterNaPi-IIc inmaintaining phosphate homeostasis. Am J Hum Genet 2006; 78:179-192
39. Ichikawa S, Sorenson AH, Imel EA et al. Intronic deletions in the SLC34A3 gene cause hereditary hypophosphatemic rickets with hypercalciuria. J Clin Endocrinol Metab 2006; 91:4022-4027
40. Lorenz-Depiereux B, Benet-Pages A, Eckstein G et al. Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3.Am J Hum Genet 2006; 78:193-201
41. Yamamoto T, Michigami T, Aranami F et al. Hereditary hypophosphatemic rickets with hypercalciuria: a study for the phosphate transporter gene type IIc and osteoblastic function. J Bone Miner Metab 2007; 25:407-413
42. Bastepe M, Juppner H. Inherited hypophosphatemic disorders in children and the evolving mechanisms of phosphate regulation. Rev Endocr Metab Disord 2008; 9:171-180
43. Jaureguiberry G, Carpenter TO, Forman S et al. A novel missense mutation in SLC34A3 that causes hereditary hypophosphatemic rickets with hypercalciuria in humans identifies threonine 137 as an important determinant ofsodium-phosphate cotransport inNaPi-IIc. AmJPhysiolRenalPhysiol2008;295:F371- 379
44. Levi M. Novel NaPi-2c mutations that cause mistargeting of NaPi-2c protein and uncoupling of Na-Pi cotransport cause HHRH. Am J Physiol Renal Physiol 2008; 295:F369-370
45. YamashitaT, Konishi M, Miyake Aet al. Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J Biol Chem 2002; 277:28265-28270
46. Segawa H, Kawakami E, Kaneko I et al. Effect of hydrolysis-resistant FGF23-R179Q on dietary phosphate regulation of the renal type-II Na/Pi transporter. Pflugers Arch 2003; 446:585-592
47. Baum M, Schiavi S, Dwarakanath V et al. Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules. Kidney Int 2005; 68:1148-1153
48. Pfister MF, Ruf I, Stange G et al. Parathyroid hormone leads to the lysosomal degradation of the renal type II Na/Pi cotransporter. Proc Natl Acad Sci USA 1998; 95:1909-1914
49. Yamamoto H, Tani Y, Kobayashi K et al. Alternative promoters and renal cell-specific regulation of the mouse type IIa sodium-dependent phosphate cotransporter gene. Biochim Biophys Acta 2005; 1732:43-52
50. Inoue Y, Segawa H, Kaneko I et al. Role of the vitamin D receptor in FGF23 action on phosphate metabolism. Biochem J 2005; 390:325-331
51. Shimada T, Yamazaki Y, Takahashi M et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 2005; 289:F1088-1095
52. Fukagawa M, Nii-Kono T, Kazama JJ. Role of fibroblast growth factor 23 in health and in chronic kidney disease. Curr Opin Nephrol Hypertens 2005; 14:325-329
53. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16:2205-2215
54. Kazama JJ, Gejyo F, Shigematsu T et al. Role of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism. Ther Apher Dial 2005; 9:328-330
55. Drezner MK, Feinglos MN. Osteomalacia due to 1alpha,25- dihydroxycholecalciferol deficiency. Association with a giant cell tumor ofbone. J Clin Invest 1977; 60:1046-1053
56. Econs MJ, Drezner MK. Tumor-induced osteomalacia-unveiling a new hormone. N Engl J Med 1994; 330:1679-1681
57. Goetz R, Beenken A, Ibrahimi OA et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 2007; 27:3417-3428
58. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009; 8:235-253
59. Kurosu H, Ogawa Y, Miyoshi M et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006; 281:6120-6123
60. Urakawa I, Yamazaki Y, Shimada T et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444:770-774
61. Kuro-o M, Matsumura Y, Aizawa H et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390:45-51
62. Yu X, Ibrahimi OA, Goetz R et al. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 2005; 146
63. Mirams M, Robinson BG, Mason RS et al. Bone as a source of FGF23: regulation by phosphate? Bone 2004; 35:1192-1199
64. Liu S, Zhou J, Tang W etal. Pathogenic role ofFgf23 inHypmice. Am JPhysiol Endocrinol Metab2006; 291:E38-49
65. Yamazaki Y, Tamada T, Kasai N et al. Anti-FGF23 neutralizing antibodies show the physiological role and structural features ofFGF23. J Bone Miner Res 2008; 23:1509-1518
66. Liu S, Vierthaler L, Tang W et al. FGFR3 and FGFR4 do not mediate renal effects of FGF23. J Am Soc Nephrol 2008; 19:2342-2350
67. Gattineni J, Bates C, Twombley K et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol 2009; 297:F282-291
68. Segawa H, Yamanaka S, Ohno Y et al. Correlation between hyperphosphatemia and type II Na-Pi cotransporter activity in klotho mice. Am J Physiol Renal Physiol 2007; 292:F769-779
69. Ichikawa S, Imel EA, Kreiter ML et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Musculoskelet Neuronal Interact 2007; 7:318-319
70. Drezner MK. PHEX gene and hypophosphatemia. Kidney Int 2000; 57:9-18
71. The HYP Consortium. A gene (PEX) with homologies to endopeptidases is mutated inpatients with X-linked hypophosphatemic rickets. Nat Genet 1995; 11:130-136
72. Beck L, Soumounou Y, Martel J et al. Pex/PEX tissue distribution and evidence for a deletion in the 3′ region of the Pex gene in X-linked hypophosphatemic mice. J Clin Invest 1997; 99:1200-1209
73. Meyer RA Jr, Meyer MH, Gray RW. Parabiosis suggests a humoral factor is involved in X-linked hypophosphatemia in mice. J Bone Miner Res 1989; 4:493-500
74. Meyer RA Jr, Tenenhouse HS, Meyer MH et al. The renal phosphate transport defect in normal mice parabiosed to X-linked hypophosphatemic mice persists after parathyroidectomy. J Bone Miner Res 1989; 4:523-532
75. Nesbitt T, Coffman TM, Griffiths R et al. Crosstransplantation ofkidneys in normal and Hyp mice. Evidence that the Hyp mouse phenotype is unrelated to an intrinsic renal defect. J Clin Invest 1992; 89:1453-1459
76. GrieffM. New insights into X-linked hypophosphatemia. Curr Opin Nephrol Hypertens 1997; 6:15-19
77. Nelson AE, Mason RS, Robinson BG. The PEX gene: not a simple answer for X-linked hypophosphataemic rickets and oncogenic osteomalacia. Mol Cell Endocrinol 1997; 132:1-5
78. Aono Y, Yamazaki Y, Yasutake J et al. Therapeutic Effects of Anti-FGF23 Antibodies in Hypophosphatemic Rickets/Osteomalacia. J Bone Miner Res 2009; 24:1879-1888
79. Kang Y, Zhang R, Lu Y et al. Crossing Talk between Pi homeostasis and Bone. J Bone Miner Res 2009; 24
80. Feng JQ, Ward LM, Liu S et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006; 38:1310-1315
81. Lorenz-Depiereux B, Bastepe M, Benet-Pages A et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 2006; 38:1248-1250
82. Fukumoto S. Physiological regulation and disorders of phosphate metabolism-pivotal role of fibroblast growth factor 23. Intern Med 2008; 47:337-343
83. Frishberg Y, Ito N, Rinat C et al. Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J Bone Miner Res 2007; 22:235-242
84. Ichikawa S, Sorenson AH, Austin AM et al. Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression. Endocrinology 2009; 150:2543-2550